List of Excipients in Branded Drug VIVIMUSTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	VIVIMUSTA	bendamustine hydrochloride	24338-270	ALCOHOL
Azurity Pharmaceuticals Inc	VIVIMUSTA	bendamustine hydrochloride	24338-270	MONOTHIOGLYCEROL
Azurity Pharmaceuticals Inc	VIVIMUSTA	bendamustine hydrochloride	24338-270	POLYETHYLENE GLYCOL 400
Azurity Pharmaceuticals Inc	VIVIMUSTA	bendamustine hydrochloride	24338-270	SODIUM HYDROXIDE
Slayback Pharma LLC	VIVIMUSTA	bendamustine hydrochloride	71225-120	ALCOHOL
Slayback Pharma LLC	VIVIMUSTA	bendamustine hydrochloride	71225-120	MONOTHIOGLYCEROL

VIVIMUSTA Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Vivimusta is a bendamustine hydrochloride product supplied as a powder for concentrate for solution for infusion. Its core excipient strategy is minimal: mannitol supports the dry formulation, while water for injection and sodium chloride solution are used during reconstitution and dilution. The commercial opportunity is therefore less likely to come from the existing Vivimusta composition and more likely to come from improved bendamustine presentations that reduce preparation time, degradation, occupational exposure, and administration risk.

The principal opportunity areas are ready-to-use or ready-to-dilute liquid formulations, improved container-closure systems, lyophilized products with longer in-use stability, and differentiated hospital products designed around closed-system transfer devices.

What is Vivimusta and which excipients does it contain?

Vivimusta is a bendamustine hydrochloride powder for concentrate for solution for infusion used in hematologic malignancies, including chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma, and multiple myeloma in specified treatment settings.[1]

Vivimusta composition

Product attribute	Vivimusta profile
Active ingredient	Bendamustine hydrochloride
Dosage form	Powder for concentrate for solution for infusion
Primary excipient	Mannitol
Reconstitution	Water for injections
Further dilution	Sodium chloride solution, commonly 0.9%
Administration	Intravenous infusion
Formulation rationale	Dry-state stability and controlled reconstitution
Key handling issue	Cytotoxic drug preparation and limited post-reconstitution stability

Mannitol is a conventional pharmaceutical bulking agent and stabilizer for sterile powder products. In this setting, it provides mass and structure to the dry cake or powder and supports reproducible reconstitution. It does not, by itself, create a major differentiation barrier because mannitol is widely used in injectable products and is generally easy to substitute with other bulking or stabilizing systems.

The commercial value of the formulation is therefore tied to the entire product system: the active ingredient, powder properties, vial, stopper, reconstitution instructions, stability profile, and pharmacy workflow.

What formulation problems create commercial opportunities for bendamustine?

Bendamustine presents several formulation challenges that can support differentiated products.

Aqueous instability

Bendamustine is susceptible to degradation in aqueous solution. The active ingredient contains a nitrogen mustard moiety and a benzimidazole structure, creating a formulation profile in which pH, temperature, concentration, light exposure, and storage duration can affect product quality.[2]

A powder product avoids prolonged aqueous storage, but it transfers operational burden to the hospital. Pharmacy staff must reconstitute the vial, dilute the product, observe handling precautions, and administer the dose within the permitted stability period.

Short in-use window

The need to use the reconstituted product within a defined time window limits scheduling flexibility. A product with longer refrigerated or room-temperature stability could reduce waste and allow batch preparation for oncology clinics.

Cytotoxic handling

Bendamustine is a hazardous antineoplastic agent. Reconstitution creates a risk of aerosolization, surface contamination, spills, and operator exposure. A ready-to-use product or closed-vial transfer design could support a premium over a conventional powder vial if it reduces preparation steps.

Dose-volume management

Bendamustine dosing is calculated by body-surface area. Vial sizes and concentration determine the number of vials required and the volume administered. A higher-concentration formulation could reduce infusion volume, but high concentration also increases the technical burden for solubility, precipitation control, stability, and injection safety.

What excipient strategies could improve Vivimusta?

The strongest strategies are those that solve a defined hospital problem without creating new regulatory or manufacturing liabilities.

1. Optimized dry powder with alternative bulking systems

A next-generation dry formulation could retain the powder presentation while improving reconstitution time, cake integrity, moisture control, and vial recovery.

Potential excipient classes include:

Excipient class	Potential role	Commercial benefit
Mannitol	Bulking agent and cake former	Low regulatory risk and familiar manufacturing profile
Trehalose or sucrose	Stabilization and glass formation	Potential improvement in solid-state stability
Amino acids	Buffering or stabilization support	May improve reconstitution and degradation control
Surfactants	Wetting and reconstitution support	May reduce foaming or incomplete dissolution
Chelating agents	Metal-ion control	May reduce catalyzed degradation if demonstrated
Buffer systems	pH control after reconstitution	May improve chemical stability, subject to tolerability
Polymer or viscosity modifiers	Physical stabilization	May complicate injectability and regulatory review

A mannitol-based platform has a commercial advantage because it is already aligned with Vivimusta's established formulation concept. A change to trehalose, sucrose, or a mixed bulking system would require comparative stability, particulate, reconstitution, and container-closure data.

2. Ready-to-dilute concentrate

A liquid concentrate could eliminate the powder-reconstitution step. The product would be supplied in a vial or bag at a controlled concentration and diluted before infusion.

The main technical barriers are:

• Long-term aqueous stability
• Degradation control across the labeled shelf life
• pH optimization
• Container adsorption
• Extractables and leachables
• Particulate control
• Light protection
• Compatibility with infusion bags and administration sets

A ready-to-dilute product has greater commercial potential than a simple excipient substitution because it can reduce pharmacy labor and preparation risk. It also creates a stronger formulation patent position if the product requires a defined concentration, pH, stabilizer combination, and storage condition.

3. Ready-to-use infusion bag

A pre-diluted infusion bag could remove both vial reconstitution and pharmacy dilution. This presentation would be operationally attractive for high-volume oncology centers, but it would face the most demanding stability and packaging requirements.

Potential approaches include:

• A stabilized solution in a single-dose infusion bag
• A dual-chamber bag that separates bendamustine from the diluent until activation
• A vial-to-bag transfer system with integrated dilution
• A polymer container selected for low adsorption and low permeability
• An overwrap providing light protection

The dual-chamber concept may offer a useful compromise. It preserves a dry or concentrated drug compartment while allowing activation immediately before administration. The key patentable elements would likely be the chamber architecture, activation mechanism, formulation concentration, and stability profile.

4. Closed-system transfer-compatible vial

A product that remains a powder but is engineered for use with closed-system transfer devices could address occupational exposure without requiring a liquid formulation.

Potential improvements include:

• Improved vial adapter compatibility
• Low-residual-volume stopper geometry
• Reduced foaming during transfer
• Controlled vacuum or pressure behavior
• Compatibility with automated compounding systems
• Vial formats optimized for robotic pharmacy preparation

This strategy may offer a lower development risk than a stable liquid formulation. Its commercial differentiation would depend on measurable reductions in preparation time, contamination risk, or drug wastage.

What patents protect bendamustine formulations?

The original bendamustine active-ingredient protection is no longer the principal commercial barrier in the United States or Europe. Current differentiation is concentrated in formulation, concentration, delivery, manufacturing, and use patents.

Patent categories relevant to Vivimusta

Patent category	Relevance to Vivimusta	Likely commercial importance
Active ingredient composition	Limited for established bendamustine products	Low
Powder formulation	Directly relevant to Vivimusta-type products	Medium
Liquid formulation	Relevant to ready-to-use competitors	High
Stabilizer combinations	Can support formulation exclusivity	High if narrow stability data are strong
Container-closure system	Relevant to hazardous-drug handling	Medium to high
Manufacturing process	Can create supply-chain barriers	Medium
Method of treatment	May protect specific indications or dosing schedules	Medium
Device or transfer system	Can support hospital workflow differentiation	Medium

The patent strength of a new bendamustine product will depend on whether the claims cover a genuine technical result. Claims limited to "bendamustine plus a conventional excipient" are vulnerable if the combination is predictable and lacks unexpected stability or handling performance. Claims tied to a defined pH range, concentration, degradation threshold, storage condition, or container system are more defensible when supported by comparative data.

What is the Orange Book status of Vivimusta?

Vivimusta is not a U.S. FDA Orange Book-listed product under that brand. It is an overseas product name and should not be treated as having U.S. Orange Book patent listings or U.S. regulatory exclusivity.

U.S. bendamustine regulatory landscape

The U.S. bendamustine market has included:

• Treanda, an original bendamustine hydrochloride product
• Bendeka, a bendamustine hydrochloride injection with a differentiated liquid formulation
• Belrapzo, another bendamustine hydrochloride injection
• Generic bendamustine hydrochloride products

The FDA approved Bendeka as a low-volume bendamustine hydrochloride injection in 2015.[3] The product was developed around a ready-to-dilute formulation rather than the conventional powder presentation. Bendeka's commercial position illustrates the value of formulation differentiation even after active-ingredient exclusivity has ended.

Vivimusta's European authorization does not automatically provide U.S. approval, U.S. market exclusivity, or U.S. patent protection. A U.S. sponsor would need to establish the appropriate regulatory pathway, such as an abbreviated application for a therapeutically equivalent product or a full application for a clinically differentiated presentation.

When does bendamustine lose exclusivity?

Bendamustine's original active-ingredient exclusivity has expired in major markets. The remaining barriers are product-specific and may include formulation patents, regulatory exclusivity, manufacturing know-how, and supply agreements.

Market	Exclusivity position
United States	Original active-ingredient exclusivity expired; generic and branded follow-on products exist
European Union	Core bendamustine exclusivity expired; national product status varies
Formulation products	May retain separate patent protection
Hospital presentations	Differentiation depends on formulation, device, supply, and contracting
Biosimilar pathway	Not applicable; bendamustine is a small molecule

Bendamustine has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic entry and formulation substitution.

Which companies are challenging bendamustine products?

Competition is primarily between branded and generic manufacturers rather than biosimilar developers.

Competitive categories

Competitor type	Product strategy	Risk to Vivimusta
Generic powder suppliers	Low-cost conventional vial	High on price
Generic liquid suppliers	Ready-to-dilute injection	High on pharmacy convenience
Branded liquid products	Formulation and handling differentiation	High in hospital accounts
Contract manufacturers	Private-label or regional supply	Medium
Device companies	Closed-system transfer or dual-chamber delivery	Indirect but potentially material

The most direct threat is a liquid bendamustine product that provides a lower preparation burden. A generic powder may be cheaper, but a stable concentrate or ready-to-dilute presentation can win hospital contracts through labor savings, reduced preparation steps, and lower wastage.

How strong is the Vivimusta patent estate?

The standalone patent strength of Vivimusta is likely limited if protection is based primarily on the known bendamustine hydrochloride powder composition with mannitol. The stronger commercial assets are regulatory approval, manufacturing reliability, regional distribution, and hospital procurement relationships.

Patent-strength assessment

Asset	Relative strength	Reason
Bendamustine active ingredient	Low	Mature compound with expired core protection
Mannitol powder composition	Low to medium	Conventional excipient and dosage form
Specific reconstitution method	Medium	Stronger if tied to validated performance
Improved dry-state stability	Medium to high	Depends on comparative data and claim scope
Ready-to-use liquid formulation	High potential	Can address a known stability and workflow problem
Closed-system packaging	Medium to high	Stronger if device and drug claims are combined
Manufacturing process	Medium	May be difficult to design around if process-specific
Method-of-use claims	Medium	Often narrower and easier to challenge

A strong portfolio would combine multiple claim families. The most valuable combination is a formulation patent covering the stability system, a container-closure patent covering the presentation, and a manufacturing patent covering the process used to produce the dosage form.

What formulation patents could protect a next-generation product?

A commercially meaningful patent strategy could target the following claim structures:

1. Bendamustine hydrochloride at a defined concentration and pH.
2. A stabilizer combination that produces a specified degradation profile.
3. A ready-to-dilute concentrate with a defined shelf life.
4. A dual-chamber container that separates the active from the diluent.
5. A vial or bag with defined adsorption and extractables performance.
6. A reconstitution process that reduces dissolution time.
7. A closed-system transfer method that minimizes operator exposure.
8. A high-concentration product that reduces infusion volume.
9. A specific bendamustine salt, polymorph, or solid-state form.
10. A manufacturing process that controls impurities or degradation products.

The most defensible claims should be supported by head-to-head data against Vivimusta-type powder products and existing liquid bendamustine products. Useful endpoints include reconstitution time, visible and subvisible particles, impurity formation, assay retention, infusion compatibility, surface contamination, and dose recovery.

What generic entry risks exist for Vivimusta?

Generic entry risk is high because bendamustine is an established small molecule with multiple products and no biosimilar barrier. The risk profile differs by product type.

Powder-product risk

A conventional generic powder can compete on price if it matches:

• Active ingredient strength
• Excipients or permissible formulation differences
• Reconstitution instructions
• Stability period
• Vial size
• Sterility and particulate specifications

Vivimusta's mannitol-based powder presentation is unlikely to provide a substantial standalone barrier against a conventional generic unless product-specific patents or regulatory requirements remain active in the relevant jurisdiction.

Liquid-product risk

Liquid products may be more difficult to copy if they rely on proprietary stabilizer combinations, narrow pH control, specialized packaging, or process controls. They also may require more extensive pharmaceutical development than a powder generic.

This creates a two-sided risk. Liquid products can threaten Vivimusta commercially, but they may also be protected by stronger formulation and packaging patents.

What licensing opportunities exist for bendamustine excipients and delivery systems?

Licensing opportunities are concentrated in platform technologies rather than bendamustine-specific active-ingredient rights.

Attractive licensing targets

• Injectable stabilization platforms
• Low-adsorption polymer containers
• Dual-chamber infusion bags
• Closed-system transfer devices
• Ready-to-use cytotoxic formulations
• Automated oncology compounding systems
• Lyophilization technologies
• High-concentration infusion technologies

A licensee would likely seek rights covering oncology injectables broadly, allowing the same platform to be used for bendamustine, melphalan, cyclophosphamide, or other hazardous drugs. The value proposition improves if the technology reduces pharmacy labor or enables longer in-use stability.

The most practical deal structure would combine an upfront payment, development milestones, and royalties tied to net sales. A hospital-focused product may also require exclusive regional rights, device integration rights, and supply commitments.

What FDA and European regulatory pathways apply?

For an improved bendamustine formulation, the regulatory pathway depends on the extent of formulation and clinical differentiation.

U.S. pathway

A reformulated bendamustine injection may be submitted through:

• An ANDA if therapeutic equivalence can be established
• A 505(b)(2) application if the product relies partly on existing bendamustine data but differs in formulation, concentration, or delivery
• A full NDA if the clinical and formulation changes are substantial

A ready-to-use or dual-chamber product would more likely require a 505(b)(2) strategy if its formulation, container, administration method, or stability profile differs materially from approved products.[4]

European pathway

In Europe, the route may involve:

• A generic application under Article 10(1)
• A hybrid application under Article 10(3)
• A national, decentralized, or mutual-recognition procedure
• A variation or line extension for an existing marketing authorization

The key regulatory questions will be pharmaceutical equivalence, stability, extractables and leachables, compatibility with infusion materials, and safe handling of the cytotoxic product.

How does Vivimusta compare with ready-to-use bendamustine products?

Criterion	Vivimusta powder	Ready-to-dilute liquid	Ready-to-use infusion
Manufacturing complexity	Lower	Medium to high	High
Aqueous shelf-life burden	Low before reconstitution	High	High
Pharmacy preparation steps	More	Fewer	Minimal
Occupational exposure opportunity	Higher	Lower	Lowest potential
Infusion-volume flexibility	Medium	Medium	Product-dependent
Excipient differentiation	Limited	High potential	High potential
Patent potential	Low to medium	Medium to high	High
Waste reduction	Limited	Improved	Potentially strongest
Hospital premium potential	Limited	Medium	High if stability is strong

Vivimusta is positioned as a conventional and potentially cost-efficient powder product. A ready-to-dilute product is better positioned to monetize workflow improvement. A ready-to-use bag has the highest potential premium but also the greatest development and supply-chain risk.

What is the commercial outlook for Vivimusta excipient innovation?

The commercial opportunity is strongest where an excipient or delivery change produces a measurable economic outcome. Hospitals are unlikely to pay a premium for a different bulking agent alone. They may pay for:

• Fewer preparation steps
• Reduced compounding time
• Lower drug wastage
• Longer post-preparation stability
• Reduced hazardous-drug exposure
• Lower infusion volume
• Better compatibility with automated pharmacy systems
• More predictable inventory and scheduling

Revenue exposure will be highest in markets with large hematology and oncology infusion volumes. The product should be positioned against pharmacy labor and total cost of administration, not only against vial acquisition price.

Key Takeaways

• Vivimusta is a bendamustine hydrochloride powder for infusion concentrate using mannitol as its principal excipient.
• The existing excipient composition has limited standalone differentiation because mannitol is conventional and widely available.
• Core bendamustine exclusivity has expired in major markets; generic entry risk is high.
• Bendamustine has no biosimilar risk because it is a small molecule.
• The strongest commercial opportunities are ready-to-dilute liquids, ready-to-use bags, dual-chamber systems, and closed-system transfer-compatible vials.
• Formulation patents should focus on stability, concentration, pH, packaging, reconstitution performance, and handling outcomes.
• A 505(b)(2) pathway may be relevant in the United States for materially differentiated bendamustine presentations.
• The commercial case depends on quantified reductions in preparation time, waste, exposure risk, and infusion burden.

FAQs

Can mannitol in Vivimusta be replaced with trehalose or sucrose?

Potentially, but the replacement would require comparative stability, sterility, reconstitution, particulate, and compatibility data. The substitute would need to provide a measurable technical advantage to support meaningful patent differentiation.

Is a ready-to-use bendamustine bag commercially attractive?

Yes, if the product maintains chemical stability through its shelf life and reduces pharmacy preparation. The main barriers are aqueous degradation, packaging compatibility, extractables and leachables, and manufacturing cost.

Does Vivimusta have U.S. Orange Book protection?

Vivimusta itself is not a U.S. Orange Book-listed product under that brand. U.S. bendamustine protection must be assessed against the applicable U.S. product, patent listings, and regulatory pathway.

Can a new bendamustine formulation receive pediatric exclusivity?

Pediatric exclusivity is not automatic. It would require an FDA-issued pediatric study request or applicable pediatric development process and successful completion of the required studies.

Which excipient technology has the highest licensing value?

A platform that enables stable, ready-to-dilute or ready-to-use cytotoxic injectables has the highest potential value. The technology is more attractive if it supports multiple oncology drugs and provides validated reductions in preparation time or drug waste.

References

1. European Medicines Agency. (n.d.). Bendamustine hydrochloride product information and European public assessment materials. European Medicines Agency.

2. National Center for Biotechnology Information. (n.d.). Bendamustine hydrochloride: Chemical and pharmaceutical information. PubChem. https://pubchem.ncbi.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2015). FDA approves Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.